(Q50646275)

17 March 2018

title

Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. (English)

1 reference

17 March 2018

ovarian hyperstimulation syndrome

1 reference

1 reference

Sherif Khattab

1

1 reference

17 March 2018

Ismail Aboul Fotouh

2

1 reference

17 March 2018

Iman Abdel Mohesn

3

1 reference

17 March 2018

Mostapha Metwally

4

1 reference

17 March 2018

Mohamed Moaz

5

1 reference

17 March 2018

publication date

1 August 2006

1 reference

17 March 2018

Reproductive BioMedicine Online

published in

1 reference

17 March 2018

volume

13

1 reference

17 March 2018

issue

2

1 reference

17 March 2018

page(s)

194-197

1 reference

17 March 2018

Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin administration improves endothelial function in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin monotherapy in lean women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

Ovarian hyperstimulation syndrome (OHSS): how much do we really know about it?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960614-1

7 January 2021

10.1016/S1472-6483(10)60614-1

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

16895631

1 reference

17 March 2018